Vesatolimod

Drug Profile

Vesatolimod

Alternative Names: GS-9620

Latest Information Update: 10 Nov 2016

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Antivirals; Pteridines; Pyrrolidines; Small molecules
  • Mechanism of Action Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B
  • Phase I HIV infections
  • Discontinued Hepatitis C

Most Recent Events

  • 01 Oct 2016 Gilead Sciences completes a phase II trial in Hepatitis B (Treatment-experienced) in US, Canada, Italy, Netherlands, New Zealand and South Korea (NCT02166047)
  • 24 Feb 2016 Preclinical data from simian immunodeficiency virus infected rhesus macaques released by Gilead
  • 01 Nov 2015 Phase-II clinical trials in Hepatitis B (Combination therapy, Treatment-naive, In adults) in Taiwan, Italy, United Kingdom (PO) after November 2015 (NCT02579382)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top